516 patents
Page 7 of 26
Utility
Salts of an LSD1 inhibitor
15 Nov 22
The present disclosure relates to tosylate salts 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the LSD1-associated or mediated diseases such as cancer.
Yongchun Pan, Wayne Han, Ganfeng Cao, Zhongjiang Jia, Jiacheng Zhou
Filed: 12 Jun 20
Utility
Tricyclic heterocycles as BET protein inhibitors
15 Nov 22
Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
Filed: 11 Dec 20
Utility
Indazole compounds and uses thereof
8 Nov 22
Alexander Sokolsky, Oleg Vechorkin, Anlai Wang, Qinda Ye, Wenqing Yao
Filed: 21 Jul 20
Utility
Ruxolitinib for the Treatment of Prurigo Nodularis
3 Nov 22
This disclosure relates to ruxolitinib, or a pharmaceutically acceptable salt thereof, and its use in treating prurigo nodularis.
Paul Smith, Jörg Wenzel
Filed: 3 May 22
Utility
Heterocyclic Compounds As Immunomodulators
3 Nov 22
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 24 Jun 22
Utility
PYRIDO[3,2-D]PYRIMIDINE Compounds As Immunomodulators
27 Oct 22
Jingwei Li, Liangxing Wu, Wenqing Yao
Filed: 27 Jun 22
Utility
Substituted Heterocyclic Derivatives As PI3K Inhibitors
27 Oct 22
Stacey Shepard, Andrew P. Combs
Filed: 22 Jun 22
Utility
Pyrazolyl Bicyclic Amines As CDK2 Inhibitors
27 Oct 22
Joshua Hummel, David M. Burns, Liangxing Wu, Wenqing Yao
Filed: 12 Apr 22
Utility
Sustained-release Dosage Forms of Ruxolitinib
20 Oct 22
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
JAK1 Pathway Inhibitors for the Treatment of Chronic Lung Allograft Dysfunction
20 Oct 22
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
Richard L. Schaub, Kevin O`Hayer
Filed: 30 Jun 22
Utility
1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase
20 Oct 22
The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
Andrew P. Combs, Eddy W. Yue, Richard B. Sparks, Wenyu Zhu, Jiacheng Zhou, Qiyan Lin, Lingkai Weng, Tai-Yuen Yue, Pingli Liu
Filed: 16 Nov 21
Utility
Crystalline forms of a FGFR inhibitor and processes for preparing the same
18 Oct 22
The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Yongchun Pan, Chongsheng Eric Shi, Ming Tao, Wayne Han, Michael Xia, Dengjin Wang, Zhongjiang Jia, Jiacheng Zhou, Qun Li
Filed: 6 Feb 20
Utility
Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
18 Oct 22
The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
Joshua Hummel, Jingwei Li, Zhenwu Li, Ding-Quan Qian, Liangxing Wu, Kaijiong Xiao, Meizhong Xu, Jeffrey C. Yang, Wenqing Yao, Fenglei Zhang, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
Filed: 4 Mar 20
Utility
Sustained-release Dosage Forms of Ruxolitinib
13 Oct 22
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 23 Jun 22
Utility
Combination Therapy Comprising an FGFR Inhibitor and a NECTIN-4 Targeting Agent
13 Oct 22
The present disclosure relates to methods of treating cancer by administering a compound, which is an Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with enfortumab vedotin.
Holly K. Koblish, Rodrigo Hess
Filed: 11 Apr 22
Utility
Heterocyclic compounds as immunomodulators
11 Oct 22
Liangxing Wu, Zhiyong Yu, Fenglei Zhang, Wenqing Yao
Filed: 26 Jun 20
Utility
Solid forms of an FGFR inhibitor and processes for preparing the same
11 Oct 22
The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.
Timothy C. Burn
Filed: 3 May 19
Utility
Imidazopyridazine and Imidazopyridine Compounds and Uses Thereof
6 Oct 22
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 9 Jun 22
Utility
Imidazopyridazine and imidazopyridine compounds and uses thereof
4 Oct 22
Jun Pan, Jeremy Roach, Song Mei, Chunhong He, Liangxing Wu, Wenqing Yao
Filed: 19 Dec 19
Utility
Crystalline Solid Forms of a Bet Inhibitor
29 Sep 22
The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.
Shili Chen, Zhongjiang Jia, Pingli Liu, Lei Qiao, Yongzhong Wu, Jiacheng Zhou, Qun Li
Filed: 2 Jun 22